Esperion Therapeutics ESPR Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's interest expense?
- Esperion Therapeutics (ESPR) reported interest expense of $19.8M in Q1 2026.
- How has Esperion Therapeutics's interest expense changed year-over-year?
- Esperion Therapeutics's interest expense increased by 1.9% year-over-year, from $19.43M to $19.8M.
- What is the long-term trend for Esperion Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Esperion Therapeutics's interest expense has grown at a 16.2% compound annual growth rate (CAGR), from $46.35M to $84.6M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.